Tegileridine

Tegileridine
Clinical data
Trade names艾苏特 (Aisute, AiSuTe)
Other namesAiSuTe; SHR-8554; SHR8554
Drug classμ-Opioid receptor agonist; Opioid; Analgesic
Legal status
Legal status
  • Rx in China
Identifiers
  • (1S,4S)-4-Ethoxy-N-[2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-1-amine
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC28H38N2O2
Molar mass434.624 g·mol−1
3D model (JSmol)
  • CCO[C@H]1CC[C@@H](C2=CC=CC=C12)NCC[C@]3(CCOC4(C3)CCCC4)C5=CC=CC=N5
  • InChI=1S/C28H38N2O2/c1-2-31-25-13-12-24(22-9-3-4-10-23(22)25)29-19-16-27(26-11-5-8-18-30-26)17-20-32-28(21-27)14-6-7-15-28/h3-5,8-11,18,24-25,29H,2,6-7,12-17,19-21H2,1H3/t24-,25-,27+/m0/s1
  • Key:YUMLNLMFBWBKSK-OHSXHVKISA-N

Tegileridine, sold under the brand name Aisute, is a drug which acts as a μ-opioid receptor agonist. It is closely related to compounds such as oliceridine, TRV734, and SHR9352, and shares a similar profile as a biased agonist selective for activation of the G protein signalling pathway over β-arrestin2 recruitment.[1]

In January 2024, tegileridine was approved in China under the brand name Aisute for the treatment of moderate to severe pain after abdominal surgery.[2]

See also

References

  1. ^ WO 2017/063509, "Oxa spiro derivative, preparation method therefor, and applications thereof in medicines", published 10 April 2018, assigned to Jiangsu Hengrui Medicine Company and Shanghai Hengrui Pharmaceutical Company Ltd . 
  2. ^ Dhillon S (June 2024). "Tegileridine: First Approval". Drugs. 84 (6): 717–720. doi:10.1007/s40265-024-02033-4. PMID 38771484.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.